Class / Patent application number | Description | Number of patent applications / Date published |
514523000 | Additional nitrogen other than cyano | 15 |
20080275114 | Inhibitors of Ccr9 Activity - Compounds of formula (I), in which R | 11-06-2008 |
20100137431 | USE OF SUBSTANCES THAT ACT AS CASCADE INHIBITORS OF THE RAF/MEK/ERK SIGNAL CASCADE, FOR PRODUCING A MEDICAMENT TO TREAT DNA AND RNA VIRUSES - The invention consists in that substances acting as cascade inhibitors of the Raf/MEK/ERK signaling pathway, in particular MEK inhibitors, are used for the production of a drug for the preventive and antiviral therapy against DNA and RNA viruses, in particular against intranuclear-replicating negative strand RNA viruses, for instance influenza or Borna disease viruses. | 06-03-2010 |
20110196035 | Temporally-Controlled Treatment of Joint Disease - A composition and method for treatment of osteoarthritis is disclosed. The composition includes at least one soluble injectable biocompatible carrier having a viscosity within prescribed limits and an amount of a calcium-channel blocker chosen in relation to the viscosity of the carrier. The concentration of the calcium-channel blocker in the joint synovial fluid is controlled according to the invention whereby effective treatment of osteoarthritis is provided. | 08-11-2011 |
20120083528 | NOVEL PROTEIN KINASE MODULATORS AND THERAPEUTIC USES THEREOF - The present invention provides new tyrphostin derivatives acting as protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, and/or which directly or indirectly affect proteins in the PTK-mediated signal transduction pathway, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer. | 04-05-2012 |
20120172429 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS - The invention provides compounds, compositions, methods, and kits for the treatment of neurogenic inflammation. | 07-05-2012 |
20120208881 | METHODS FOR CONCOMITANT ADMINISTRATION OF COLCHICINE AND A SECOND ACTIVE AGENT - Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided. | 08-16-2012 |
20120270940 | Closthioamides - This invention relates to the field of biologically active compounds and specifically to closthioamides, pharmaceutical compositions comprising these compounds, and their use as antibiotic, antifungal, and/or cytotoxic agent. | 10-25-2012 |
20120277307 | Method for Treating Osteoarthritis - A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed. | 11-01-2012 |
20130210911 | METHOD AND COMPOSITION FOR TREATING A DISEASE OR CONDITION RELATED TO OREXIN RECEPTOR 1, OREXIN RECEPTOR 2, SOMATOSTATIN RECEPTOR 2 OR DOPAMINE D2L RECEPTOR - Disclosed herein are methods and composition for treating a disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D | 08-15-2013 |
20160023996 | Cancer Chemotherapeutic Agent/Formulation, Manufacture and Use Thereof - A cancer chemotherapeutic agent that is particularly kinase suppressing and/or any other signaling pathway interfering agents and pharmaceutical formulations/compositions involving the same and its process of manufacture is provided. A potential the cancer chemotherapeutic agent is provided which apart from stated anticancer activity as a proven kinase suppressing and/or any other signaling pathway interfering agent could also involve specific potential binding affinity towards the intramolecular G-Quadruplex DNA structure and/or other potential quadruplex forming sequences over duplex DNA structures favours further diverse end use and application including but not limited to antiaging, antiangiogenic, antiproliferative, antitumor, antibiotic, antiviral, antifungal and multiple anticancer therapeutics, and also possesses favourable cytotoxicity values towards uncontrollably proliferative cells by inducing apoptosis irrespective of cells' p53 status, without being cytotoxic to normal cells. | 01-28-2016 |
20160184256 | METHOD OF TREATING DISORDERS OF THE CARDIOVASCULAR SYSTEM AND A PHARMACEUTICAL AGENT - A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. | 06-30-2016 |
514524000 | The cyano is bonded directly to a benzene ring | 4 |
20100292324 | Multi-Substituted Diarylanilines as Non-Nucleoside HIV Reverse Transcriptase Inhibitors, and Preparation and Use Thereof - The present invention relates to multi-substituted m-diarylanilines or pharmaceutically acceptable salts thereof, wherein X, R | 11-18-2010 |
20120289595 | NOVEL BIARYLAMIDE DERIVATIVE AND COMPOSITIONS CONTAINING THE DERIVATIVE AS AN ACTIVE INGREDIENT - The present invention relates to a novel biarylamide derivative and a pharmaceutical composition or a cosmetic composition comprising the same as an active ingredient. More particularly, the present invention relates to a novel biarylamide derivative, a pharmaceutical composition or a cosmetic composition for preventing or treating a pigmentation disorder caused by an abnormal excess of melanin or a disease caused by melanocyte hyperplasia comprising the same as an active ingredient. The biarylamide derivative of the present invention inhibits melanin production and thus inhibits melanocyte hyperplasia. Therefore, a cosmetic composition comprising the biarylamide is excellent in a whitening effect, and a pharmaceutical composition comprising the biarylamide is effective in the prevention or treatment of pigmentation disorders of skin such as lentigo, melasma, freckle, etc. and malignant melanoma. | 11-15-2012 |
20150011628 | SUBSTITUTE DIPHENYLAMINE COMPOUNDS USE THEREOF AS ANTITUMOR AGENTS - The invention relates to substituted diphenylamine compounds using as antitumor agents. The structure of the compounds is represented as the general formula (I): | 01-08-2015 |
20160052865 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS LSD1 INHIBITORS - The invention relates to cyclopropylamine compounds, in particular the compounds of Formula (I), and their use in therapy, including e.g. in the treatment or prevention of cancer, a neurological disease or condition, or viral infection. | 02-25-2016 |